140 related articles for article (PubMed ID: 38615411)
21. Low-calcemic, highly antiproliferative, 1-difluoromethyl hybrid analogs of the natural hormone 1alpha,25-dihydroxyvitamin D3: design, synthesis, and preliminary biological evaluation.
Peleg S; Petersen KS; Suh BC; Dolan P; Agoston ES; Kensler TW; Posner GH
J Med Chem; 2006 Dec; 49(25):7513-7. PubMed ID: 17149880
[TBL] [Abstract][Full Text] [Related]
22. 13,13-Dimethyl-des-C,D analogues of (20S)-1α,25-dihydroxy-2-methylene-19-norvitamin D₃ (2MD): total synthesis, docking to the VDR, and biological evaluation.
Plonska-Ocypa K; Sibilska I; Sicinski RR; Sicinska W; Plum LA; DeLuca HF
Bioorg Med Chem; 2011 Dec; 19(23):7205-20. PubMed ID: 22018918
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological activities of new 1alpha,25-dihydroxy-19-norvitamin D3 analogs with modifications in both the A-ring and the side chain.
Shimizu M; Miyamoto Y; Kobayashi E; Shimazaki M; Yamamoto K; Reischl W; Yamada S
Bioorg Med Chem; 2006 Jun; 14(12):4277-94. PubMed ID: 16503143
[TBL] [Abstract][Full Text] [Related]
24. New 1alpha,25-dihydroxy-19-norvitamin D3 analogs with a frozen A-ring conformation.
Glebocka A; Sicinski RR; Plum LA; DeLuca HF
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):46-50. PubMed ID: 20214980
[TBL] [Abstract][Full Text] [Related]
25. New C15-substituted active vitamin D3.
Shindo K; Kumagai G; Takano M; Sawada D; Saito N; Saito H; Kakuda S; Takagi K; Ochiai E; Horie K; Takimoto-Kamimura M; Ishizuka S; Takenouchi K; Kittaka A
Org Lett; 2011 Jun; 13(11):2852-5. PubMed ID: 21539305
[TBL] [Abstract][Full Text] [Related]
26. New 2-alkylidene 1alpha,25-dihydroxy-19-norvitamin D3 analogues of high intestinal activity: synthesis and biological evaluation of 2-(3'-alkoxypropylidene) and 2-(3'-hydroxypropylidene) derivatives.
Glebocka A; Sicinski RR; Plum LA; Clagett-Dame M; DeLuca HF
J Med Chem; 2006 May; 49(10):2909-20. PubMed ID: 16686534
[TBL] [Abstract][Full Text] [Related]
27. Recent results on A-ring modification of 1alpha,25-dihydroxyvitamin D3: design and synthesis of VDR-agonists and antagonists with high biological activity.
Saito N; Honzawa S; Kittaka A
Curr Top Med Chem; 2006; 6(12):1273-88. PubMed ID: 16848741
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological activity of 22-iodo- and (E)-20(22)-dehydro analogues of 1alpha,25-dihydroxyvitamin D3.
Sicinski RR; DeLuca HF
Bioorg Med Chem; 1999 Dec; 7(12):2877-89. PubMed ID: 10658592
[TBL] [Abstract][Full Text] [Related]
29. 2-Ethyl and 2-ethylidene analogues of 1alpha,25-dihydroxy-19-norvitamin D(3): synthesis, conformational analysis, biological activities, and docking to the modeled rVDR ligand binding domain.
Sicinski RR; Rotkiewicz P; Kolinski A; Sicinska W; Prahl JM; Smith CM; DeLuca HF
J Med Chem; 2002 Aug; 45(16):3366-80. PubMed ID: 12139448
[TBL] [Abstract][Full Text] [Related]
30. Recent developments of 19-nor-1,25-dihydroxyvitamin D3 analogues.
Zhang CF; Wan RZ; Liu ZP
ChemMedChem; 2013 Aug; 8(8):1249-60. PubMed ID: 23788554
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of novel 6-substituted analogs of 1α,25-dihydroxy-19-norvitamin D3.
Sokolowska K; Sicinski RR; Mouriño A; Plum LA; DeLuca HF
J Steroid Biochem Mol Biol; 2013 Jul; 136():30-3. PubMed ID: 23116698
[TBL] [Abstract][Full Text] [Related]
32. New highly calcemic 1 alpha,25-dihydroxy-19-norvitamin D(3) compounds with modified side chain: 26,27-dihomo- and 26,27-dimethylene analogs in 20S-series.
Sicinski RR; Prahl JM; Smith CM; DeLuca HF
Steroids; 2002 Mar; 67(3-4):247-56. PubMed ID: 11856548
[TBL] [Abstract][Full Text] [Related]
33. Highly potent cell differentiation-inducing analogues of 1alpha,25-dihydroxyvitamin D3: synthesis and biological activity of 2-methyl-1,25-dihydroxyvitamin D3 with side-chain modifications.
Fujishima T; Zhaopeng L; Konno K; Nakagawa K; Okano T; Yamaguchi K; Takayama H
Bioorg Med Chem; 2001 Feb; 9(2):525-35. PubMed ID: 11249144
[TBL] [Abstract][Full Text] [Related]
34. Removal of the 26-methyl group from 19-nor-1α,25-dihydroxyvitamin D₃ markedly reduces in vivo calcemic activity without altering in vitro VDR binding, HL-60 cell differentiation, and transcription.
Grzywacz P; Chiellini G; Plum LA; Clagett-Dame M; DeLuca HF
J Med Chem; 2010 Dec; 53(24):8642-9. PubMed ID: 21105677
[TBL] [Abstract][Full Text] [Related]
35. New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues.
Sicinski RR; Prahl JM; Smith CM; DeLuca HF
J Med Chem; 1998 Nov; 41(23):4662-74. PubMed ID: 9804706
[TBL] [Abstract][Full Text] [Related]
36. Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification.
Tocchini-Valentini G; Rochel N; Wurtz JM; Moras D
J Med Chem; 2004 Apr; 47(8):1956-61. PubMed ID: 15055995
[TBL] [Abstract][Full Text] [Related]
37. Novel 2-alkyl-1alpha,25-dihydroxy-19-norvitamin D3: efficient synthesis with Julia olefination, evaluation of biological activity and development of new analyzing system for co-activator recruitment.
Arai MA; Kittaka A
Anticancer Res; 2006; 26(4A):2621-31. PubMed ID: 16886672
[TBL] [Abstract][Full Text] [Related]
38. The first locked side-chain analogues of calcitriol (1alpha,25-dihydroxyvitamin D3) induce vitamin D receptor transcriptional activity.
Pérez-García X; Rumbo A; Larriba MJ; Ordóñez P; Muñoz A; Mouriño A
Org Lett; 2003 Oct; 5(22):4033-6. PubMed ID: 14572242
[TBL] [Abstract][Full Text] [Related]
39. Low-calcemic, highly antiproliferative, 23-oxa ether analogs of the natural hormone 1 alpha,25-dihydroxyvitamin D3: design, synthesis, and preliminary biological evaluation.
Petersen KS; Dolan PM; Kensler TW; Peleg S; Posner GH
J Med Chem; 2007 Nov; 50(23):5824-32. PubMed ID: 17924616
[TBL] [Abstract][Full Text] [Related]
40. Structure-activity relationships of 19-norvitamin D analogs having a fluoroethylidene group at the C-2 position.
Kobayashi E; Shimazaki M; Miyamoto Y; Masuno H; Yamamoto K; DeLuca HF; Yamada S; Shimizu M
Bioorg Med Chem; 2007 Feb; 15(3):1475-82. PubMed ID: 17110116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
